About: Yttrium (90Y) clivatuzumab tetraxetan

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells. The drug was developed by Immunomedics, Inc. In March 2016 the phase III PANCRIT-1 trial in metastatic pancreatic cancer was terminated early due to lack of improvement of overall survival.

Property Value
dbo:abstract
  • إتريوم (90إ) كليفاتوزوماب تتراكسيتان هو دواء مصمم لعلاج . ويتكون من كليفاتوزوماب والذي هو جسم مضاد وحيد النسيلة مع عامل التمخلب الذي يرتبط مع نظير الإتريوم-90 المشع الذي يدمر الخلايا السرطانية. طورته ويسوق تحت اسم تجاري هبام4-سايد (hPAM4-Cide). (ar)
  • Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells. The drug was developed by Immunomedics, Inc. In March 2016 the phase III PANCRIT-1 trial in metastatic pancreatic cancer was terminated early due to lack of improvement of overall survival. (en)
dbo:casNumber
  • 943976-23-6
dbo:fdaUniiCode
  • 2L271110ED
dbo:wikiPageID
  • 33058043 (xsd:integer)
dbo:wikiPageLength
  • 3071 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1084076852 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:c
  • 6496 (xsd:integer)
dbp:casNumber
  • 943976 (xsd:integer)
dbp:chemspiderid
  • none (en)
dbp:drugName
  • Yttrium clivatuzumab tetraxetan (en)
dbp:h
  • 9952 (xsd:integer)
dbp:mabType
  • mab (en)
dbp:n
  • 1716 (xsd:integer)
dbp:o
  • 2014 (xsd:integer)
dbp:s
  • 44 (xsd:integer)
dbp:source
  • zu/o (en)
dbp:target
dbp:type
  • mab (en)
dbp:unii
  • 2 (xsd:integer)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 470634923 (xsd:integer)
dbp:watchedfields
  • changed (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • إتريوم (90إ) كليفاتوزوماب تتراكسيتان هو دواء مصمم لعلاج . ويتكون من كليفاتوزوماب والذي هو جسم مضاد وحيد النسيلة مع عامل التمخلب الذي يرتبط مع نظير الإتريوم-90 المشع الذي يدمر الخلايا السرطانية. طورته ويسوق تحت اسم تجاري هبام4-سايد (hPAM4-Cide). (ar)
  • Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells. The drug was developed by Immunomedics, Inc. In March 2016 the phase III PANCRIT-1 trial in metastatic pancreatic cancer was terminated early due to lack of improvement of overall survival. (en)
rdfs:label
  • إتريوم (90إ) كليفاتوزوماب تتراكسيتان (ar)
  • Yttrium (90Y) clivatuzumab tetraxetan (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
foaf:name
  • Yttrium (90Y) clivatuzumab tetraxetan (en)
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License